SKFOF:OTC-Sika AG (USD)

COMMON STOCK | Specialty Chemicals |

Last Closing

USD 312.164

Change

-3.78 (-1.20)%

Market Cap

USD 51.52B

Volume

131.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-22 )

Largest Industry Peers for Specialty Chemicals

Symbol Name Price(Change) Market Cap
AIQUY Air Liquide SA ADR

N/A

USD 116.28B
AIQUF L'Air Liquide S.A

N/A

USD 116.17B
PTCAY Chandra Asri Petrochemical Tbk..

N/A

USD 51.18B
SXYAY Sika AG ADR

N/A

USD 49.20B
GVDNY Givaudan SA ADR

N/A

USD 44.76B
GVDBF Givaudan SA

N/A

USD 43.25B
NVZMF Novozymes A/S B

N/A

USD 28.49B
NVZMY Novozymes AS

N/A

USD 28.47B
EMSHF EMS-CHEMIE HOLDING AG

N/A

USD 19.37B
SYIEY Symrise Ag PK

N/A

USD 16.86B

ETFs Containing SKFOF

XSPR:LSE Xtrackers MSCI Europe Mat.. 8.69 % 0.00 %

N/A

USD 0.04B
DXSC:F Xtrackers Stoxx Europe 60.. 8.69 % 0.00 %

N/A

USD 0.04B
STPX:SW SPDR® MSCI Europe Materi.. 5.90 % 0.00 %

N/A

USD 0.42B
CHSRII:SW UBS(Lux)Fund Solutions .. 5.58 % 0.00 %

N/A

USD 0.30M
CHSR:XETRA UBS(Lux)Fund Solutions .. 5.12 % 0.00 %

N/A

USD 0.17B
CHSRI:SW UBS ETF (CH) - MSCI Switz.. 4.99 % 0.00 %

N/A

USD 368,190.74B
CHSRIA:SW UBS ETF (CH) MSCI Switzer.. 4.99 % 0.00 %

N/A

USD 492,935.36B
XSLI:SW Xtrackers SLI UCITS ETF 1.. 4.67 % 0.00 %

N/A

USD 0.28B
SLICHA:SW UBS ETF (CH) – SLI® (C.. 4.65 % 0.00 %

N/A

USD 1.03B
DXS0:F Xtrackers - SLI UCITS ETF 4.64 % 0.00 %

N/A

USD 0.28B
CSSLI:SW iShares SLI® ETF (CH) 4.62 % 0.00 %

N/A

USD 0.58B
TINT ProShares Smart Materials.. 4.60 % 0.00 %

N/A

USD 1.67M
SMIEX:SW iShares SLI UCITS ETF (DE.. 4.51 % 0.00 %

N/A

USD 5,933.96B
C030:F Lyxor DJ Switzerland Tita.. 4.04 % 0.00 %

N/A

USD 0.01B
CBCH30:SW 3.90 % 0.00 %

N/A

N/A
SMICHA:SW UBS ETF (CH) – SMI® (C.. 3.61 % 0.00 %

N/A

USD 2.49B
CSSMI:SW iShares SMI® ETF (CH) 3.58 % 0.00 %

N/A

USD 2.06B
XSMC:SW Xtrackers Switzerland UCI.. 3.44 % 0.00 %

N/A

USD 0.46B
XSMI:SW Xtrackers Switzerland UCI.. 3.44 % 0.00 %

N/A

USD 1.24B
DBXS:F Xtrackers - Switzerland U.. 3.12 % 0.00 %

N/A

USD 1.24B
SWICHA:SW UBS ETF (CH) – MSCI Swi.. 2.92 % 0.00 %

N/A

USD 0.56B
SW2CHA:SW UBS(Lux)Fund Solutions .. 2.90 % 0.00 %

N/A

USD 0.44B
SW2CHB:SW UBS(Lux)Fund Solutions .. 2.90 % 0.00 %

N/A

USD 1.50B
SW2UKD:SW UBS(Lux)Fund Solutions .. 2.90 % 0.00 %

N/A

USD 0.03B
SWEUAH:SW UBS ETF (CH) – MSCI Swi.. 2.88 % 0.00 %

N/A

USD 0.13B
SWUSAH:SW UBS ETF (CH) – MSCI Swi.. 2.85 % 0.00 %

N/A

USD 0.40B
CHEUR:SW UBS(Lux)Fund Solutions .. 2.85 % 0.00 %

N/A

USD 0.18B
CHEURD:SW UBS(Lux)Fund Solutions .. 2.85 % 0.00 %

N/A

USD 4.24M
CHUSD:SW UBS(Lux)Fund Solutions .. 2.85 % 0.00 %

N/A

USD 0.08B
CHUSDD:SW UBS(Lux)Fund Solutions .. 2.85 % 0.00 %

N/A

USD 0.01B
S2HGBD:SW UBS(Lux)Fund Solutions .. 2.85 % 0.00 %

N/A

USD 0.06B
S2HGBA:SW UBS(Lux)Fund Solutions .. 2.85 % 0.00 %

N/A

USD 8.13M
UC93:LSE UBS MSCI Switzerland 20/3.. 2.81 % 0.00 %

N/A

USD 8.13M
UC94:LSE UBS(Lux)Fund Solutions .. 2.81 % 0.00 %

N/A

USD 0.06B
SPICHA:SW UBS ETF (CH) – SPI® (C.. 2.81 % 0.00 %

N/A

USD 1.30B
FLSW Franklin FTSE Switzerland.. 2.76 % 0.09 %

N/A

USD 0.06B
CHSPI:SW iShares Core SPI® ETF (C.. 2.72 % 0.00 %

N/A

USD 3.22B
SPF1:F SSgA SPDR ETFs Europe II .. 1.08 % 0.00 %

N/A

N/A
ZPRC:F SSgA SPDR ETFs Europe II .. 1.08 % 0.00 %

N/A

USD 0.61B
SPF1:XETRA SPDR Refinitiv Global Con.. 1.08 % 0.00 %

N/A

USD 0.33B
ZPRC:XETRA SPDR Thomson Reuters Glob.. 1.08 % 0.00 %

N/A

USD 0.53B
GCVB:SW SPDR Refinitiv Global Con.. 1.08 % 0.00 %

N/A

USD 0.71B
GCVC:SW SPDR Refinitiv Global Con.. 1.08 % 0.00 %

N/A

USD 0.10B
GLCB:LSE SPDR Thomson Reuters Glob.. 1.07 % 0.00 %

N/A

USD 0.65B
EWL iShares MSCI Switzerland .. 0.00 % 0.47 %

N/A

USD 1.17B
PIZ Invesco DWA Developed Mar.. 0.00 % 0.80 %

N/A

USD 0.14B
MTRL:LSE SPDR® MSCI Europe Materi.. 0.00 % 0.00 %

N/A

USD 0.42B
STP:PA SSgA SPDR ETFs Europe II .. 0.00 % 0.00 %

N/A

USD 0.42B
EXI1:F iShares SLI UCITS ETF (DE.. 0.00 % 0.00 %

N/A

USD 0.38B
EXV8:F iShares STOXX Europe 600 .. 0.00 % 0.00 %

N/A

USD 0.11B
SPYP:F SSgA SPDR ETFs Europe II .. 0.00 % 0.00 %

N/A

USD 0.42B
C030:XETRA Amundi Index Solutions - .. 0.00 % 0.00 %

N/A

USD 0.13B
DBXS:XETRA Xtrackers - Switzerland U.. 0.00 % 0.00 %

N/A

USD 1.34B
DXS0:XETRA Xtrackers SLI UCITS ETF 1.. 0.00 % 0.00 %

N/A

USD 0.26B
DXSC:XETRA Xtrackers - Stoxx Europe .. 0.00 % 0.00 %

N/A

USD 0.05B
EXI1:XETRA iShares SLI UCITS ETF (DE.. 0.00 % 0.00 %

N/A

USD 0.37B
EXV8:XETRA iShares STOXX Europe 600 .. 0.00 % 0.00 %

N/A

USD 0.11B
SPYP:XETRA SPDR® MSCI Europe Materi.. 0.00 % 0.00 %

N/A

USD 0.38B
1391:TSE 0.00 % 0.00 %

N/A

N/A
FGGE:CA Franklin Global Growth Fu.. 0.00 % 0.00 %

N/A

CAD 0.01B

Market Performance

  Market Performance vs. Industry/Classification (Specialty Chemicals) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -2.75% 50% F 44% F
Dividend Return 1.10% 21% F 24% F
Total Return -1.66% 50% F 44% F
Trailing 12 Months  
Capital Gain 13.06% 72% C 70% C-
Dividend Return 1.28% 16% F 15% F
Total Return 14.34% 70% C- 68% D+
Trailing 5 Years  
Capital Gain 108.11% 94% A 88% B+
Dividend Return 8.61% 33% F 27% F
Total Return 116.72% 92% A 87% B+
Average Annual (5 Year Horizon)  
Capital Gain 20.09% 71% C- 66% D+
Dividend Return 21.00% 64% D 63% D
Total Return 0.91% 16% F 20% F
Risk Return Profile  
Volatility (Standard Deviation) 35.55% 60% D- 64% D
Risk Adjusted Return 59.07% 92% A 91% A-
Market Capitalization 51.52B 98% N/A 98% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.